The 30-month deadline for entering the U.S. national stage of a PCT application, what to note for 2026 material preparation and priority claims, if missed, only the bypass procedure remains

Conclusion first: 30 months is not a flexible deadline; if missed, basically only the bypass procedure remains.

The deadline for entering the U.S. national stage of a PCT application is 30 months from the earliest priority date, a deadline jointly set by 35 U.S.C. §371 and 37 C.F.R. §1.491. In most cases, it cannot be extended; if missed, one can only switch to a bypass continuation application under 37 C.F.R. §1.53(b) or rely on limited restoration procedures. When preparing materials in 2026, the priority certificate, IDS disclosure, and claim translation are the three most likely bottlenecks.

When exactly does the 30-month period start? Don't be fooled by the term 'filing date'.

Many clients encountering this issue for the first time instinctively take the PCT international filing date as the starting point. That is not correct. The 30 months are calculated from the 'earliest priority date'—if the PCT itself claims priority from an earlier Chinese application, the starting point is the filing date of that Chinese application, not the PCT filing date. This means the actual available time is often several months shorter than imagined.

There is an even more hidden situation: when there are multiple applications in the priority chain, such as a Chinese application followed by a U.S. provisional application, and then the PCT filing. In this case, the earliest priority date is the earliest date in the chain. In practice, we generally recommend that clients immediately create a deadline countdown table after PCT filing, listing all the 30-month and national stage entry deadlines, rather than waiting until the 28th month to start.

What must be submitted when entering the U.S. national stage is clearly listed in 37 C.F.R. §1.494: English translations of the specification, claims, drawings (if any), and abstract, plus the application fee, search fee, and examination fee. If the translation is later amended, it cannot go beyond the scope of the original PCT publication, as explicitly constrained by 35 U.S.C. §371(c).

Priority claims must be handled at entry; supplementing later comes at a cost.

Priority claims do not take effect automatically. When entering the U.S. national stage, the priority information must be correctly filled in the Application Data Sheet (ADS), and a copy of the priority document or an electronic exchange authorization must be submitted as required. For a Chinese earlier application, the priority document can be electronically exchanged via the WIPO DAS system, provided the access code is correctly entered in the ADS; an error in this step will directly result in the priority claim not being recognized.

If the priority claim is omitted at entry, it can later be restored by petition under 37 C.F.R. §1.55(c), but it requires a statement of unintentional delay and payment of the corresponding fee. In practice, examiners will review such restoration requests, but the approval rate is not 100%, especially when the delay is long. So our advice is simple: double-check the priority information before entry; it is much cheaper than fixing it afterward.

Another reminder: whether the priority claim is established directly affects the subsequent novelty assessment and the calculation of the novelty grace period. The U.S. is primarily an absolute novelty system with a limited grace period. Once the priority date is pushed back, any public disclosures of your own exhibition materials, samples, or crowdfunding pages in between may become prior art. This type of risk occurs frequently among cross-border e-commerce hardware clients.

For 2026 material preparation, translation and IDS are the two major problem areas.

Translation quality is a high-risk area for triggering restriction requirements and subsequent 101 and 112 issues from examiners. Mistranslating 'comprising' and 'consisting of' in claims can directly change the scope of protection; in method claims, the subject omitted in Chinese must be supplied in English. We generally recommend that clients have a translator with U.S. patent practice experience review the translation, rather than using a general technical translator.

The Information Disclosure Statement (IDS) is another area. 37 C.F.R. §1.56 imposes a duty of candor on applicants toward the examiner, and in principle, counterpart patents from the Chinese earlier application, the corresponding PCT search report, and examination opinions from other countries in the family must be submitted. Many clients encountering this for the first time ask: do we need to submit the prior art cited by the Chinese examiner? Yes. If not submitted, after the patent is granted, the other party may use it against you in invalidation or litigation, or even trigger an inequitable conduct defense.

On timing, we usually recommend completing the final translation at least 60 days before the 30-month deadline, leaving 4 to 6 weeks for IDS preparation and ADS verification. This is not conservatism—it's leaving a buffer for contingencies.

After the deadline: the bypass route is not as simple as "refiling"

What if the 30 months have passed? The most conventional path is to file a new U.S. continuation application (bypass continuation) under 37 C.F.R. §1.53(b), claiming priority to the PCT application. Note that what is claimed here is priority to the PCT application, not the earlier priority claimed by the PCT—if the PCT itself also claims priority to an earlier Chinese application, the earliest priority date can still be claimed via §119 or §365(c), but only if this bypass application is filed within 12 months from the PCT filing date (design patents have separate rules, which are not discussed here).

If the 12 months have also passed, there is still restoration. 37 C.F.R. §1.452 and §1.490 allow restoration of the right to enter the national stage under certain conditions, but the threshold is not low—it requires proving that the delay was "unavoidable," and the fees are higher. In practice, successful restorations we have seen are mostly in provable situations such as agent error or system failure; a pure "forgot" is very hard to get through.

Another point that is easily overlooked: if the U.S. national stage is not entered by the deadline, the PCT application itself becomes ineffective after the international phase ends and does not automatically preserve any U.S. rights. To preserve them, action must be taken within the deadline or a timely switch to the bypass route. For clients with multi-country portfolios, we suggest also reviewing other countries' intellectual property legal services, because the calculation of the 30-month deadline and restoration rules are not uniform across countries.

In which situations should you enter early rather than cutting it close to the 30 months?

Not all cases are suited to dragging on until the 29th month. If the product is already on sale in the U.S. market, or you are preparing to participate in events such as CES or Amazon Prime Day that will disclose a large amount of technical detail, entering early allows you to receive an office action sooner and makes it easier to finalize the claim layout before disclosure. The average U.S. patent examination cycle is currently around 20 months (varying widely by technology field), so entering early means earlier grant and earlier enforcement.

Conversely, if the technical solution is still iterating and the claims still require major changes, entering at the deadline and using the opportunity to amend under PCT Article 19 or Article 34 also has its value. The criterion is the product launch schedule and competitor movements, not merely cost. For combined protection involving trademarks, copyrights, and patents, you may also refer toU.S. and EU Intellectual Property Legal Servicesand coordinate the timelines together.

In addition, the USPTO fee structure is still being adjusted in 2026, with notable differences among large entities, small entities, and micro entities; micro entities can receive an 80% reduction. Confirming entity status before entry can save a not-insignificant amount. If the entity status declaration is filled out incorrectly and later discovered, back fees will be required and patent validity may also be affected.

A few pitfalls that are easy to step into—let's make them clear in advance

First, the inventor information in the ADS must be consistent with the PCT request. Inconsistency will result in a notice requiring correction, and the correction period is usually only 2 months; extensions are possible but the fees are not low.

Second, if an overly early priority is claimed upon entry (for example, the priority document itself does not support the claims), the examiner may issue a notice requiring deletion of the priority claim. At that point, either the claims must be amended or the priority must be abandoned—both paths affect the layout.

Third, if amendments under Article 34 were made during the PCT international phase, it must be clearly stated upon entry into the U.S. which version is the basis. If the wrong version is used, subsequent amendments will be rejected as new matter.

Fourth, for clients involved in standard-essential patents or intending to go through the UPC, the linkage between the U.S. application and the European application must also be considered. Europe's 30-month deadline calculation differs from that of the U.S.; do not manage all countries with one calendar. For the overall overseas layout framework, see the overseas intellectual property section.

The foreign-related intellectual property team of Guangdong Zhiming Law Firm has long handled U.S., EU, and PCT national phase matters. If you need to verify the 30-month deadline for a specific case or evaluate a bypass option, please call 0755-25986969 to schedule a consultation.

Disclaimer: This article is compiled based on publicly available laws and regulations and practical experience. It is for general reference only and does not constitute legal advice on any specific case. Patent laws, fee standards, and examination practices in various countries may be adjusted at any time. For handling individual cases, please rely on the in-person assessment of a professional agent or attorney.